Leadership & Expert Views - Cancer Currents Blog
Commentaries from scientific leaders at NCI and other institutions about cancer research topics, programs, and initiatives.
-
Dr. Dinah Singer, co-chair of the Cancer Moonshot Blue Ribbon Panel, provides an update to the cancer community on the science being supported under the Moonshot initiative.
-
NCI’s Dr. Lyndsay Harris provides an update on the NCI-MATCH trial, including the opening of new trial treatment arms and the addition of new laboratories to perform testing on tumor samples of prospective trial participants.
-
October 2018 marked Dr. Norman Sharpless’s one-year anniversary as NCI director. He reflects on noteworthy events from the past 12 months and his excitement about leading NCI at such a critical juncture in the history of cancer research.
-
Researchers are shifting how they assess diet and cancer risk, looking beyond the impact of individual foods or nutrients on health, and taking a more holistic approach, considering dietary patterns across the lifespan.
-
With the increasing reliance on advanced technologies and the rise of big data in cancer research, NCI launched the R50 Research Specialist Award to help sustain a stable workforce of experienced scientists who can take fullest advantage of these tools and resources.
-
NCI has released its Fiscal Year 2020 Annual Plan and Budget Proposal. The plan represents NCI’s best professional judgement on the optimum funding needed to make the most rapid progress against cancer.
-
NCI Director Dr. Norman Sharpless discusses efforts between NCI and FDA to advance progress against cancer, including initiatives to improve labeling of patient tumor and tissue samples and to address challenges presented by new tobacco products.
-
Dr. Supriya Mohile discusses the unique issues experienced by older adults with cancer and efforts to incorporate geriatric assessment into patient care, including the publication of recent ASCO clinical guidelines on geriatric cancer care.
-
NCI’s SEER program is expanding in size and operating a series of innovative pilot studies. As Dr. Lynne Penberthy explains, these studies are setting the stage for the routine collection of more clinical and genomic data that will help researchers better understand cancer and its impact.
-
NCI is supporting a new research network to develop biomarkers for cancer immunotherapy. In this interview, NCI’s Dr. Helen Chen and Magdalena Thurin explain the networks’ structure and its goals.